About Us

Cimeio Therapeutics

Cimeio is an applied gene editing and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs™ (SCIP), which has the potential to transform hematopoietic stem cell transplant. Cimeio’s technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in HSCs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.

Leadership

Thomas Fuchs

Thomas Fuchs

Chief Executive Officer

Tristan Imbert

Tristan Imbert

Chief Financial Officer

Lukas Jeker, MD/PhD

Lukas Jeker, MD/PhD

Founder, SVP Gene Editing

Daniel Stark, PhD

Daniel Stark, PhD

Chief Manufacturing Officer

Stefanie Urlinger, PhD

Stefanie Urlinger, PhD

Chief Scientific Officer

Thomas Winkler, MD

Thomas Winkler, MD

Chief Medical Officer

Thomas Fuchs

Thomas Fuchs

Chief Executive Officer

Tristan Imbert

Tristan Imbert

Chief Financial Officer

Lukas Jeker, MD/PhD

Lukas Jeker, MD/PhD

SVP Gene Editing

Daniel Stark, PhD

Daniel Stark, PhD

Chief Manufacturing Officer

Stefanie Urlinger, PhD

Stefanie Urlinger, PhD

Chief Scientific Officer

Thomas Winkler, MD

Thomas Winkler, MD

Chief Medical Officer

Scientific Advisory Board

Suneet Agarwal, MD, PhD

Suneet Agarwal, MD, PhD

Assoc. Prof. Harvard Medical School

Jeff Bluestone, PhD

Jeff Bluestone, PhD

CEO, Sonoma Bio

Toni Cathomen, MD

Toni Cathomen, MD

Prof. University of Freiburg

Corey Cutler, MD, MPH, FRCPC

Corey Cutler, MD, MPH, FRCPC

Assoc. Prof. Harvard Medical School

Fyodor Urnov, PhD, Chair

Fyodor Urnov, PhD, Chair

Prof. University of California Berkeley

Suneet Agarwal, MD, PhD

Suneet Agarwal, MD, PhD

Jeff Bluestone, PhD

Jeff Bluestone, PhD

Toni Cathomen, MD

Toni Cathomen, MD

Corey Cutler, MD, MPH, FRCPC

Corey Cutler, MD, MPH, FRCPC

Fyodor Urnov, PhD, Chair

Fyodor Urnov, PhD, Chair

Board of Directors

Lukas Jeker, MD/PhD

Lukas Jeker, MD/PhD

Founder, SVP Gene Editing

Markus Enzelberger, Ph.D.

Markus Enzelberger, Ph.D.

Partner at Versant Ventures

Alexander Mayweg, Ph.D.

Alexander Mayweg, Ph.D.

President of Ridgeline Discovery and Managing Director at Versant Ventures

Team

Marc Bigler

Marc Bigler

Thomas Burgold

Thomas Burgold

Anna Camus

Anna Camus

Valentin Do Sacramento

Valentin Do Sacramento

Laura Garcia Prat

Laura Garcia Prat

Eva-Maria Grossjohann

Eva-Maria Grossjohann

Tanja Herrmann

Tanja Herrmann

Marcel Heugel

Marcel Heugel

Andreja Knezevic

Andreja Knezevic

Mariah Kohlbrenner

Mariah Kohlbrenner

Frank Lehmann

Frank Lehmann

Emiel Ten Buren

Emiel Ten Buren

Saniye Yumlu

Saniye Yumlu

Cimeio Team